Edgar Filing: Wright Frank J - Form 4

| Wright Frank Form 4 | J | | | | | | | | | | |
|---|---|---|--|------------------------|-----------|---|--|---|-----------|--|--|
| February 08, 2 | 2013 | | | | | | | | | | |
| FORM | Л | | | | | | | | PPROVAL | | |
| | UNITEDS | | SECURITIES AND EXCHANGE (Washington, D.C. 20549 | | | | COMMISSION | OMB Number: | 3235-0287 | | |
| Check this if no longe subject to Section 16. Form 4 or Form 5 obligations may contin <i>See</i> Instruc 1(b). | r STATEMI Filed pursu sue. Section 17(a) | ant to Section 1 of the Public U | OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES to Section 16(a) of the Securities Exchange Act of 1934, he Public Utility Holding Company Act of 1935 or Section (h) of the Investment Company Act of 1940 | | | | | | | | |
| (Print or Type Re | esponses) | | | | | | | | | | |
| 1. Name and Ad Wright Frank | Symbol ALEXI | 2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN] | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
| (Last) C/O ALEXIO PHARMACE KNOTTER D | (Month/D | 3. Date of Earliest Transaction(Month/Day/Year)02/06/2013 | | | | Director 10% Owner X Officer (give title Other (specify below) below) SVP, President Alxn Pharm Intl | | | | | |
| CHESHIRE, | (Street) | | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting | | | |
| CHESIIKE, | C1 00410 | | | | | | Person | | | | |
| (City) | (State) (Z | Cip) Tabl | e I - Non-D | erivative S | Securiti | ies Ace | quired, Disposed o | f, or Beneficial | lly Owned | | |
| 1.Title of Security (Instr. 3) | 2 | | | | | | SecuritiesHBeneficially()OwnedHFollowing()Reported() | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | | |
| Common Stock, par value \$.0001 per share | 02/06/2013 | | Code V A | Amount 2,200 (1) | or (D) | Price \$ 0 | Transaction(s) (Instr. 3 and 4) 14,700 | D | | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: Wright Frank J - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. 5. Number of Transactio/Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | e Expiration Date (Month/Day/Year) (A) ed of | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | |
|---|---|---|---|--|---------------|---|--------------------|---|-------------------------------------|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Option to Purchase Common Stock | \$ 93.83 | 02/06/2013 | | А | 29,600 (2) | 05/06/2013 | 02/06/2023 | Common Stock | 29,600 |

Reporting Owners

| Reporting Owner Name / Address | | Relationships | | | | | |
|---|-----------|---------------|-----------|--------------------------------|-------|--|--|
| | | Director | 10% Owner | Officer | Other | | |
| Wright Frank J C/O ALEXION PHARMACE 352 KNOTTER DRIVE CHESHIRE, CT 06410 | EUTICALS | | | SVP, President Alxn Pharm Intl | | | |
| Signatures | | | | | | | |
| /s/ Frank J 0 | 2/08/2013 | | | | | | |

Wright 02/08/20

Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Award of Restricted Stock Units under 2004 Incentive Plan. 50% vests on the second anniversary of the grant date, and 1/8 vests every 6 months thereafter.
- (2) 1/16 vests every 3 months following grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.